Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy

Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy

Akebia is a lot like other small biotech companies with quality management teams executing well but ignored by investors for reasons that don't really make much sense fundamentally.

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.

Akebia Expands Anemia Pill Partnership to Include Europe, China Rights

Akebia Expands Anemia Pill Partnership to Include Europe, China Rights

The new licensing deal between Akebia and Otsuka expands upon a pact made last December for U.S. commercial rights.

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales

When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.